Zyprexa

Ranbaxy is India's biggest drugmaker, with $1.16 billion in 2004 sales.

Today's ruling is the second time a U.S.

court has rebuffed efforts by a generic-drug company challenging a patent on the main compound for a drug.

In April, a judge in Indiana upheld the compound patent for Eli Lilly & Co.'s The case is Pfizer Inc.

v.

Ranbaxy Laboratories Ltd., 03cv209, U.S.

District Court, District of Delaware (Wilmington).

To contact the reporters on this story: Phil Milford in Wilmington, Delaware, at pmilford@bloomberg.net; Nicole Ostrow in New York at nostrow@bloomberg.net.

Last Updated: December 16, 2005 17:29 EST ©2005 Bloomberg L.P.

All rights reserved.

Terms of Service Privacy Policy Trademarks Site Map Help Feedback About Bloomberg Log In/Register Advertising 日本語サイト ...

He said, “We have reached a point where there just are not enough taxes or taxpayer money to keep Medicaid going,” adding, “Medicaid eventually will bankrupt every state in the nation.”With the rising Medicaid expenses to state budgets, states are scrambling to rein in costs and meet budgetary constraints.

Ohio Representative, Catherine Barrett, expressed concerns for these issues: “Ohio's Medicaid spending on drugs for mental health, needs a Task Force and an Oversight Commission to investigate the spike in Medicaid spending on antipsychotic drugs.”In an interview with WIMA-AM Radio in November 2005, Hogan had this to say on OMAP in Ohio: “…frankly it didn’t work very well for us and we’ve discontinued it…..Increasingly it’s clear that the scientists don’t have pretty good information to give the doctors about which works best……So we thought, and frankly I thought at one point in time that this kind of algorithm where you’d give the docs, ‘Try this first, try this second,’ would be a good idea but it just hasn’t worked that well.” That must have been a pretty expensive lesson in Ohio.Today and TomorrowThis is not a complete report on what is happening today regarding the implementation of these program...

Sales next year are expected to increase 7-9 per cent to more than $15bn (€12.6 billion).

Barriers to this growth are tough US trends in its important markets of antipsychotics and antidepressants.

E-mail this page to a colleague Print in friendly format Copyright - Unless otherwise stated all contents of this web site are © 2000/2005 – Decision News Media SAS – All Rights Reserved.

For permission to reproduce any contents of this web site, please email our Syndication department: .

Full details for the use of materials on this site can be found in the Terms & Conditions.

Subscribe to Other Decision News Media E-newsletters - Pharmaceutical & Science Pharmaceutical Technology Drug Discovery Pharmaceutical Contract Services Biopharmaceutical Science and Business Laboratory Equipment Scientific Computing & Instrumentation Microscopy Spectroscopy Chromatography and Separations Sciences Packaging Technologies & Markets B2B Marketing Newsletter Confirm registration E-newsletters for food & beverage All Decision News Media sites Food & Beverage Development - Europe - Supplements & Nutrition - Europe - Food Processing & Packaging - Europe - Food Marketing and Retailing - Supplements & Nutrition - North America - Beverage Tech...